Drug
Amifampridine clinical trials
Also written Firdapse.
- studies test it
- 16
- open now
- 1
- in phase 3
- 9
- first study started
- 1994
Keep track of what changes. Save the Amifampridine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 1994 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 6
- Phase 3
- 9
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 8
Catalyst Pharmaceuticals, Inc. (7) · Assistance Publique - Hôpitaux de Paris (2) · Augusta University (1) · Centre Hospitalier Universitaire, Amiens (1) · Wake Forest University Health Sciences (1) · Jacobus Pharmaceutical (1) · FDA Office of Orphan Products Development (1) · University of Aarhus (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Amifampridine is read from its arms, and is right about nine times in ten.
Testing it · 16
- Pyridostigmine and Amifampridine for Myasthenia GravisRecruitingPhase 3Leiden University Medical CenterNCT05919407Written as Amifampridine (base) with modified release
- Firdapse for Post-BOTOX Vocal WeaknessCompletedPhase 2Augusta UniversityNCT05123053Written as Amifampridine
- Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of BotulismCompletedPhase 2/3Centre Hospitalier Universitaire, AmiensNCT01441557Written as 3,4-diaminopyridine
- Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinACompletedPhase 1Wake Forest University Health SciencesNCT05769478Written as Amifampridine
- Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)TerminatedPhase 3Catalyst Pharmaceuticals, Inc.NCT03579966Written as Amifampridine Phosphate
- Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MGCompletedPhase 3Catalyst Pharmaceuticals, Inc.NCT03304054Written as Amifampridine Phosphate
- Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3TerminatedPhase 2Catalyst Pharmaceuticals, Inc.NCT03819660Written as Amifampridine Phosphate 10 MG Oral Tablet
- Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 PatientsCompletedPhase 2Catalyst Pharmaceuticals, Inc.NCT03781479Written as Amifampridine Phosphate
- Amifampridine Phosphate for the Treatment of Congenital Myasthenic SyndromesCompletedPhase 3Catalyst Pharmaceuticals, Inc.NCT02562066Written as amifampridine phosphate
- DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada SyndromeTerminatedPhase 3Assistance Publique - Hôpitaux de ParisNCT00701077Written as 3,4-Di-amino-Pyridine
- Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)CompletedPhase 3Catalyst Pharmaceuticals, Inc.NCT02970162Written as Amifampridine Phosphate
- A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)CompletedPhase 3Catalyst Pharmaceuticals, Inc.NCT01377922Written as Amifampridine Phosphate
- Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic SyndromeCompletedPhase 2Jacobus PharmaceuticalNCT01511978Written as Continuous 3,4-DAP
- Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic SyndromeCompletedNot applicableFDA Office of Orphan Products DevelopmentNCT00004832Written as 3,4-diaminopyridine
- Efficacy of 3,4-DAP in Fatigue Associated With Multiple SclerosisCompletedPhase 3Assistance Publique - Hôpitaux de ParisNCT00190268Written as 3,4-diaminopyridine
- Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic StimulationCompletedPhase 2University of AarhusNCT00342381Written as 3,4-diaminopyridine
Codes
What other systems call Amifampridine · ClinicalTrials.gg INT006805
- MeSH (NLM) D000077770AmifampridineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) RU4S6E2G0JAMIFAMPRIDINEConfirmed FDA, NLM, Wikidata
- RxNorm 2106338Confirmed FDA, Wikidata
- Wikidata Q411707amifampridineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82687AmifampridineOne source FDA
- DrugBank DB11640One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077770 | Amifampridine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | RU4S6E2G0J | AMIFAMPRIDINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2106338 | — | Confirmed FDA, Wikidata |
| Wikidata | Q411707 | amifampridine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82687 | Amifampridine | One source FDA |
| DrugBank | DB11640 | — | One source Wikidata |
Also registered as amifampridine phosphate (UNII 8HF8FIN815 · RxNorm 2106337).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.